Mo
Morphic Ther (Lilly)
Waltham MAFounded 2015120 employees
Private CapbiotechAcquiredGIImmunology
Platform: Integrin
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Polazasiran | MOR-5209 | Phase 3 | 4 | KIF18A | FSGSAngelman | ||
| Doxarapivir | MOR-2199 | Phase 2 | 2 | EGFR | CTCLOCD | ||
| Zorilemzoparlimab | MOR-9171 | Approved | 1 | CDK2 | AMLBladder Ca | ||
| Zanulemzoparlimab | MOR-4063 | Phase 3 | 1 | AHR | FTDPBC |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)